GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Debt-to-Asset

Regenerex Pharma (Regenerex Pharma) Debt-to-Asset : 4.87 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Debt-to-Asset?

Regenerex Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.98 Mil. Regenerex Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.17 Mil. Regenerex Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $0.85 Mil. Regenerex Pharma's debt to asset for the quarter that ended in Dec. 2023 was 4.87.


Regenerex Pharma Debt-to-Asset Historical Data

The historical data trend for Regenerex Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Debt-to-Asset Chart

Regenerex Pharma Annual Data
Trend Nov09 Nov10 Nov11 Nov12 Nov13 Nov14 Mar17 Mar18 Mar22 Mar23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.75 - - 32.87 82.29

Regenerex Pharma Quarterly Data
May14 Aug14 Nov14 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.90 82.29 1.66 4.37 4.87

Competitive Comparison of Regenerex Pharma's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Regenerex Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerex Pharma's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regenerex Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Regenerex Pharma's Debt-to-Asset falls into.



Regenerex Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Regenerex Pharma's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Regenerex Pharma's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenerex Pharma  (OTCPK:PEPT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Regenerex Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerex Pharma (Regenerex Pharma) Business Description

Traded in Other Exchanges
N/A
Address
5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines